| 000 | 01105 a2200253 4500 | ||
|---|---|---|---|
| 005 | 20250517200133.0 | ||
| 008 | ####s 0 0 eng d | ||
| 022 | _a1569-8041 | ||
| 024 | 7 |
_a10.1093/annonc/mdx812 _2doi |
|
| 040 |
_aNLM _beng _cNLM |
||
| 100 | 1 | _aCzuczman, M S | |
| 245 | 0 | 0 |
_aPhase II trial of galiximab (anti-CD80 monoclonal antibody) plus rituximab (CALGB 50402): Follicular Lymphoma International Prognostic Index (FLIPI) score is predictive of upfront immunotherapy responsiveness. _h[electronic resource] |
| 260 |
_bAnnals of oncology : official journal of the European Society for Medical Oncology _c11 2018 |
||
| 300 |
_a2271 p. _bdigital |
||
| 500 | _aPublication Type: Journal Article; Published Erratum | ||
| 700 | 1 | _aLeonard, J P | |
| 700 | 1 | _aJung, S | |
| 700 | 1 | _aJohnson, J L | |
| 700 | 1 | _aHsi, E D | |
| 700 | 1 | _aByrd, J C | |
| 700 | 1 | _aCheson, B D | |
| 773 | 0 |
_tAnnals of oncology : official journal of the European Society for Medical Oncology _gvol. 29 _gno. 11 _gp. 2271 |
|
| 856 | 4 | 0 |
_uhttps://doi.org/10.1093/annonc/mdx812 _zAvailable from publisher's website |
| 999 |
_c28033765 _d28033765 |
||